Literature DB >> 35221866

Variances in Antiviral Memory T-Cell Repertoire of CD45RA- and CD62L-Depleted Lymphocyte Products Reflect the Need of Individual T-Cell Selection Strategies to Reduce the Risk of GvHD while Preserving Antiviral Immunity in Adoptive T-Cell Therapy.

Caroline Mangare1, Sabine Tischer-Zimmermann1, Agnes Bonifacius1, Sebastian B Riese1, Anna Christina Dragon1, Rainer Blasczyk1, Britta Maecker-Kolhoff2, Britta Eiz-Vesper1.   

Abstract

INTRODUCTION: Viral infections and reactivations still remain a cause of morbidity and mortality after hematopoietic stem cell transplantation due to immunodeficiency and immunosuppression. Transfer of unmanipulated donor-derived lymphocytes (DLI) represents a promising strategy for improving cellular immunity but carries the risk of graft versus host disease (GvHD). Depleting alloreactive naïve T cells (TN) from DLIs was implemented to reduce the risk of GvHD induction while preserving antiviral memory T-cell activity. Here, we compared two TN depletion strategies via CD45RA and CD62L expression and investigated the presence of antiviral memory T cells against human adenovirus (AdV) and Epstein-Barr virus (EBV) in the depleted fractions in relation to their functional and immunophenotypic characteristics.
METHODS: T-cell responses against ppEBV_EBNA1, ppEBV_Consensus and ppAdV_Hexon within TN-depleted (CD45RA-/CD62L-) and TN-enriched (CD45RA+/CD62L+) fractions were quantified by interferon-gamma (IFN-γ) ELISpot assay after short- and long-term in vitro stimulation. T-cell frequencies and immunophenotypic composition were assessed in all fractions by flow cytometry. Moreover, alloimmune T-cell responses were evaluated by mixed lymphocyte reaction.
RESULTS: According to differences in the phenotype composition, antigen-specific T-cell responses in CD45RA- fraction were up to 2 times higher than those in the CD62L- fraction, with the highest increase (up to 4-fold) observed after 7 days for ppEBV_EBNA1-specific T cells. The CD4+ effector memory T cells (TEM) were mainly responsible for EBV_EBNA1- and AdV_Hexon-specific T-cell responses, whereas the main functionally active T cells against ppEBV_Consensus were CD8+ central memory T cells (TCM) and TEM. Moreover, comparison of both depletion strategies indicated that alloreactivity in CD45RA- was lower than that in CD62L- fraction.
CONCLUSION: Taken together, our results indicate that CD45RA depletion is a more suitable strategy for generating TN-depleted products consisting of memory T cells against ppEBV_EBNA1 and ppAdV_Hexon than CD62L in terms of depletion effectiveness, T-cell functionality and alloreactivity. To maximally exploit the beneficial effects mediated by antiviral memory T cells in TN-depleted products, depletion methods should be selected individually according to phenotype composition and CD4/CD8 antigen restriction. TN-depleted DLIs may improve the clinical outcome in terms of infections, GvHD, and disease relapse if selection of pathogen-specific donor T cells is not available.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Alloreactivity; Low precursor frequency; Naïve T-cell depletion; T-cell response

Year:  2021        PMID: 35221866      PMCID: PMC8832244          DOI: 10.1159/000516284

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  76 in total

1.  Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.

Authors:  Ann M Leen; Uluhan Sili; Barbara Savoldo; Alan M Jewell; Pedro A Piedra; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

2.  Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.

Authors:  A Gratwohl; R Brand; F Frassoni; V Rocha; D Niederwieser; P Reusser; H Einsele; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

3.  Naive and memory T cells induce different types of graft-versus-host disease.

Authors:  Suparna Dutt; Diane Tseng; Joerg Ermann; Tracy I George; Yin Ping Liu; Corrine R Davis; C Garrison Fathman; Samuel Strober
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

Review 4.  The Epstein-Barr virus and its association with human cancers.

Authors:  K R Baumforth; L S Young; K J Flavell; C Constandinou; P G Murray
Journal:  Mol Pathol       Date:  1999-12

5.  Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: implications for differential CD45 expression in T cell memory formation.

Authors:  M Merkenschlager; L Terry; R Edwards; P C Beverley
Journal:  Eur J Immunol       Date:  1988-11       Impact factor: 5.532

Review 6.  Functional signatures of protective antiviral T-cell immunity in human virus infections.

Authors:  Alexandre Harari; Valérie Dutoit; Cristina Cellerai; Pierre-Alexandre Bart; Renaud A Du Pasquier; Giuseppe Pantaleo
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

Review 7.  Adoptive immunotherapy with virus-specific T cells.

Authors:  Shigeo Fuji; Markus Kapp; Götz Ulrich Grigoleit; Hermann Einsele
Journal:  Best Pract Res Clin Haematol       Date:  2011-09       Impact factor: 3.020

Review 8.  Virus-specific T-cell therapies for patients with primary immune deficiency.

Authors:  Michael D Keller; Catherine M Bollard
Journal:  Blood       Date:  2020-02-27       Impact factor: 25.476

Review 9.  Antiviral T-cell therapy.

Authors:  Ann M Leen; Helen E Heslop; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

10.  ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.

Authors:  Denis Claude Roy; Irwin Walker; Johan Maertens; Philippe Lewalle; Eduardo Olavarria; Dominik Selleslag; Sylvie Lachance; Marc Buyse; Kun Wang; Jeroen Rovers; Irene Santi; Halvard Bonig; Andrew Sandler; Jurjen Velthuis; Stephan Mielke
Journal:  Leukemia       Date:  2020-02-11       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.